NASDAQ$SIBN

SI-BONE Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

SI-BONE generated record quarterly revenues and demonstrated strong business momentum despite the COVID-19 pandemic.

SI-BONE, Inc. reported a 12% increase in worldwide revenue for the fourth quarter of 2020, reaching $22.1 million. The company's U.S. revenue also increased by 12% to $20.7 million. Despite the lingering effects of the COVID-19 pandemic, SI-BONE sees strong underlying momentum in its business and provides full year 2021 revenue guidance of $92 million to $94 million, or 25% to 28% growth.

  • Worldwide revenue of $22.1 million, a 12% increase year-over-year.
  • U.S. revenue of $20.7 million, a 12% increase year-over-year.
  • Gross margin of 90% remained consistent with the prior year.
  • Provided full year 2021 revenue guidance of $92 million to $94 million, representing 25% to 28% growth.

Headline financials

Total Revenue

$22.1M

Previous: $19.8M+11.8%
EPS (adj)

-$0.28

Previous: -$0.36+22.2%
Capital Expenditures

$817K

No prior period
Free Cash Flow

-$8.7M

No prior period
Net Income

-$9M

Previous: -$9.1M+1.1%
Operating Income

-$7.9M

Previous: -$8.49M+6.9%
Gross Profit

$19.9M

Previous: $17.8M+11.8%
Cash & Equivalents

$53.6M

Previous: $10.4M+413.5%
Total Assets

$223M

Previous: $117M+90.7%
Stock-Based Comp

$3.17M

No prior period

Revenue & EPS history

SI-BONE · Revenue · Quarterly

$22.1M

Q4 2020+11.8%vs Q4 2019
Beat estimate in 9 of 13 quarters(69%)
ActualEstimate

Forward guidance

The Company expects total 2021 revenue of approximately $92 million to $94 million, representing growth of 25% to 28% compared to full year 2020.

Tailwinds

  • Positive trends in business
  • Anticipates more normalized case scheduling
  • Anticipates elective procedure levels progressing throughout the year
  • Expects total 2021 revenue of approximately $92 million to $94 million
  • Represents growth of 25% to 28% compared to full year 2020

Headwinds

  • COVID-19 has had and may continue to have an impact on business
  • The impact of the COVID-19 pandemic on the Company's business has differed by geography and region
  • 2021 outlook is highly sensitive to assumptions on a global recovery
  • Assumes more normalized case scheduling
  • Assumes elective procedure levels progressing throughout the year

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

-1.8%

Avg return

Earnings day

-1.3%

Avg return

5 days after

+0.0%

Avg return

30 days after

40%

12 / 30 earnings

Positive

+16.2%

Q4 2022

Best reaction

-23.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.3%+15.3%+25.1%
Q4 2025-1.0%-0.6%-17.8%
Q3 2025+16.1%+11.1%+20.0%
Q1 2025+15.6%+29.8%+33.8%
Q4 2024+5.6%+3.7%-19.9%
Q3 2024-17.5%-18.8%-14.5%
Q2 2024-3.6%-5.2%+10.2%
Q1 2024+10.4%+8.0%-1.1%
Q4 2023-12.4%-15.7%-22.0%
Q3 2023-4.7%-12.4%-0.9%
Q2 2023-12.5%-9.6%-7.1%
Q1 2023+9.6%-0.3%+13.9%
Q4 2022+16.2%+19.5%+14.0%
Q3 2022-23.1%-16.4%-26.5%
Q2 2022-6.4%+0.1%+3.5%
Q1 2022-23.7%-27.6%-12.2%
Q4 2021+2.4%+3.2%+3.2%
Q3 2021-7.8%-10.9%-13.6%
Q2 2021-15.1%-18.9%-18.3%
Q1 2021-7.0%-7.5%-17.2%
Q4 2020+4.0%+6.6%+8.3%
Q3 2020+3.2%+0.5%+10.7%
Q2 2020+13.6%+17.7%+31.7%
Q1 2020+9.0%+11.9%+16.3%
Q4 2019-11.9%-21.7%-28.9%
Q3 2019-4.4%-4.5%-0.6%
Q2 2019+6.8%+10.7%+11.3%
Q1 2019-3.9%-8.1%-1.5%
Q4 2018-4.6%-3.6%-9.4%
Q3 2018-3.0%+4.8%+10.5%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q1 2016
Q1 2015
Q4 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro